868 abstracts found.



Results filter

Intensity of radical resection for lung cancer in relation to survival outcomes in England

Year:

Session type:

Henrik Mller1, Ruth Jack1, Karen Linklater1, Victoria Coupland1, Elizabeth Davies1, Mick Peake2

1King's College London, Thames Cancer Registry, London, UK, 2National Cancer Intelligence Network, London, UK

The mitochondrial ATP transporter VDAC1 /Porin is required for TRAIL-induced apoptosis in non-small cell lung cancer

Year:

Session type:

Alex Chacko, Ian Paul, Fabio Liberante, Dean Fennell

Queen's University Belfast, Belfast, UK

Introduction: New strategies for improving prognosis in breast cancer

Year:

Session type:

Ian Smith

The Institute of Cancer Research, Royal Marsden Hospital, Sutton, UK

Patients report improvements in continuity of care when quality of life assessments are used routinely in oncology practice: secondary outcomes of a randomised controlled trial

Year:

Session type:

Galina Velikova1, Ada Keding1, Clare Harley1, Kim Cocks2, Adam Smith3, Laura Booth1, Penny Wright1, Peter Selby1, Julia Brown2

1St James's Institute of Oncology, University of Leeds, UK, 2Clinical Trials Research Unit, University of Leeds, UK, 3Centre for Health & Social Care, University of Leeds, UK

Auto-antibodies in breast cancer: a new diagnostic tool?

Year:

Session type:

John Robertson

University of Nottingham, UK

Introduction – Infection and cancer: epidemiology, biology and prevention

Year:

Session type:

Lawrence Young

University of Birmingham, UK

Combined targeted therapies in breast cancer

Year:

Session type:

Stephen Johnston

The Institute of Cancer Research, Royal Marsden Hospital, Sutton, UK

Molecular epidemiology of infection-related cancer

Year:

Session type:

Charles Rabkin

Viral Epidemiology Branch, National Cancer Institute, USA

Bone targeted therapy: modifying the soil to prevent metastatic seeding

Year:

Session type:

Robert Coleman

Cancer Research Centre, Weston Park Hospital, University of Sheffield, UK

Role of KSHV infection in the pathogenesis of sarcoma and lymphoma

Year:

Session type:

Thomas Schulz

Hannover Medical School, Germany

Understanding how pioneer factors regulate estrogen receptor function in breast cancer cells

Year:

Session type:

Jason S Carroll, Kelly A Holmes

Cancer Research UK/Cambridge Research Institute, Cambridge, UK

Helicobacter pylori infection and gastric cancer: from cause to cure

Year:

Session type:

Jean Crabtree

Leeds Institute for Molecular Medicine, University of Leeds, UK

Merkel cell polyomavirus in Merkel cell carcinoma: pilot project to develop biomarkers for validation in a subsequent clinical trial

Year:

Session type:

Simon Chanas1, David Blackbourn1, Rachel Wheat1, Ditte Hedegaard1, Claudia Roberts2, Naiem Moiemen2, Margaret Sherman2, Mark Pritchard1, Jane Steele1, Jeremy Marsden2, Neil Steven1

1University of Birmingham, UK, 2University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

Regulation of glucose and energy metabolism by Hypoxia-Inducible Factor 1

Year:

Session type:

Gregg Semenza

Johns Hopkins University School of Medicine, USA

Genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD

Year:

Session type:

Christopher Ricketts1, Julia Forman2, Eleanor Rattenbury3, Nicola Bradshaw4, Fiona MacDonald3, Eamonn Maher1

1CR-UK Renal Molecular Oncology Group, Medical & Molecular Genetics, University of Birmingham, UK, 2University of Cambridge, UK, 3West Midlands Region Genetics Service, Birmingham Womens Hospital, UK, 4Duncan Guthrie Institute of Medical Genetics, Yorkhill Hospital, Glasgow, UK

Inhibition of pyruvate dehydrogenase kinase activity promotes apoptosis in colorectal cancer cells

Year:

Session type:

B Madhok, S Yeluri, S Perry, TA Hughes, DG Jayne

The Leeds Teaching Hospitals NHS Trust, University of Leeds, Leeds, West Yorkshire, UK

Lactate dehydrogenase-5 is an independent prognostic factor in colorectal cancer: implications for future therapies

Year:

Session type:

S Yeluri1, P Prasad3, B Madhok1, H Thorpe4, SL Perry2, TA Hughes2, KR Prasad1, P Quirke2, DG Jayne1

1Leeds Institute of Molecular Medicine, University of Leeds & St. James's University Hospital, Leeds, UK, 2Leeds Institute of Molecular Medicine, University of Leeds, UK, 3St.James's University Hospital, Leeds, UK, 4Clinical Trials Research Unit, University of Leeds, UK

Introduction – Improving patient care: quality assurance of psychological care

Year:

Session type:

Michael Sharpe

University of Edinburgh, UK

SMaRT quality assurance: making sure the treatment given is the treatment intended

Year:

Session type:

Jane Walker

University of Edinburgh, UK

Introduction – From the genome to the clinic: connecting data for better health

Year:

Session type:

Sir Alex Markham1 and Julie Clifton2
1University of Leeds, UK; and 2NCRI Consumer Liaison Group, UK

This symposium, jointly hosted by NCIN and the NCRI Informatics Initiative, will look at different means of utilising the increasing quantity of routine and research data available about cancer patients to directly improve outcomes from the disease.

Maintaining the quality of a complex behavioural intervention to promote early presentation of cancer in a randomised controlled trial

Year:

Session type:

Amanda Ramirez

Guys, Kings and St Thomas School of Medicine, London, UK

Cancer registries and the electronic health record

Year:

Session type:

Eric Holowaty

Cancercare, Ontario, Canada

Quality issues in complex intervention randomised controlled trials

Year:

Session type:

John Norrie

Robertson Centre for Biostatistics, University of Glasgow, UK

Connecting from primary to secondary care: the data experience

Year:

Session type:

Tjeerd van Staa

General Practice Research Database, UK

Training health professionals to deliver an intervention to promote early presentation of breast cancer: a pilot study in the NHS Breast Screening Programme

Year:

Session type:

Caroline Burgess, Emma Teasdale, Lynne Omar, Lorraine Tucker, Amanda Ramirez

Institute of Psychiatry/Kings College London, London, UK

Data sharing and health outcomes

Year:

Session type:

Stephen Friend

Merck, USA

Cognitive behaviour therapy for menopausal symptoms following breast cancer treatment

Year:

Session type:

Myra Hunter

King's College London, London, UK

Integration, analysis and meta-mining of data to aid disease diagnosis, prognosis and treatment response

Year:

Session type:

Marketa Zvelebil1, Costas Mitsopoulos2

1Breakthrough Breast Cancer Research, London, UK, 2Institute for Cancer Research, London, UK

Tricyclic antidepressants protect against glioma and colorectal cancer

Year:

Session type:

Alex Walker1, Kenneth Muir2, Timothy Bates3, Timothy Card1

1The University of Nottingham, UK, 2Royal College of Medicine, London, UK, 3New-Use Therapeutics Limited, Nottingham, UK

Trends in laparoscopic colorectal tumour resections across England between 1998 and 2006

Year:

Session type:

Thomas Clarke, Phil Quirke, David Forman, James Thomas, Eva Morris

University of Leeds, UK

Introduction: Hypoxia and the Warburg effect

Year:

Session type:

Peter Ratcliffe

University of Oxford, UK

Hypoxia and tumour metabolism: approach towards new anti-cancer targets

Year:

Session type:

Jacques Pouyssegur

Institute of Signaling, Developmental Biology and Cancer Research, Nice, France

Fumarate hydratase and other genetic insights into tumour metabolism

Year:

Session type:

Ian Tomlinson

University of Oxford, UK

The need for diseases models with “commons” as a mean to share data

Year:

Session type:

Stephen Friend
Merck, USA

Utility of circulating tumour cells in drug development for lung cancer

Year:

Session type:

Caroline Dive
Paterson Institute for Cancer Research, Manchester, UK

Using biomarkers in early stage development

Year:

Session type:

Josep Tabernero
Vall d'Hebron University Hospital, Barcelona, Spain

Introduction: Societal attitudes to death and dying

Year:

Session type:

Mike Richards1 and Teresa Tate2
1National Cancer Director (England), UK, and 2Marie Curie Cancer Care, UK

Using biomarkers in early stage development

Year:

Session type:

Josep Tabernero
Vall d'Hebron University Hospital, Barcelona, Spain

Using biomarkers in early stage development

Year:

Session type:

Josep Tabernero
Vall d'Hebron University Hospital, Barcelona, Spain

Introduction: Societal attitudes to death and dying

Year:

Session type:

Mike Richards1 and Teresa Tate2
1National Cancer Director (England), UK, and 2Marie Curie Cancer Care, UK

Introduction: Societal attitudes to death and dying

Year:

Session type:

Mike Richards1 and Teresa Tate2
1National Cancer Director (England), UK, and 2Marie Curie Cancer Care, UK

The need for diseases models with “commons” as a mean to share data

Year:

Session type:

Stephen Friend
Merck, USA

Utility of circulating tumour cells in drug development for lung cancer

Year:

Session type:

Caroline Dive
Paterson Institute for Cancer Research, Manchester, UK

Using biomarkers in early stage development

Year:

Session type:

Josep Tabernero
Vall d'Hebron University Hospital, Barcelona, Spain

Introduction: Societal attitudes to death and dying

Year:

Session type:

Mike Richards1 and Teresa Tate2
1National Cancer Director (England), UK, and 2Marie Curie Cancer Care, UK

The need for diseases models with “commons” as a mean to share data

Year:

Session type:

Stephen Friend
Merck, USA

Utility of circulating tumour cells in drug development for lung cancer

Year:

Session type:

Caroline Dive
Paterson Institute for Cancer Research, Manchester, UK

Using biomarkers in early stage development

Year:

Session type:

Josep Tabernero
Vall d'Hebron University Hospital, Barcelona, Spain

Introduction: Societal attitudes to death and dying

Year:

Session type:

Mike Richards1 and Teresa Tate2
1National Cancer Director (England), UK, and 2Marie Curie Cancer Care, UK

The need for diseases models with “commons” as a mean to share data

Year:

Session type:

Stephen Friend
Merck, USA